Work

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042)

Year: 2017

Type: article

Source: Lung Cancer

DOI: 10.1016/j.lungcan.2017.01.021

Authors: Dong-Wan Kim, Edward B. Garon, Aminah Jatoi, Dorothy M. Keefe, Mario E. Lacouture, Stephen Sonis, Diana Gernhardt, Tao Wang, Nagdeep Giri, Jim P. Doherty, Sashi Nadanaciva, Joseph O’Connell, Eric Sbar, Byoung Chul Cho

Institutions: Seoul National University, Seoul National University Hospital, University of California, Los Angeles, Mayo Clinic, The University of Adelaide, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Pfizer (United States), Yonsei University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Pfizer, National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W2585339553

FWCI: 0.607

Cites: 13

Cited by: 13

Related to: 10